1. Home
  2. VRTX vs EPD Comparison

VRTX vs EPD Comparison

Compare VRTX & EPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$477.08

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Logo Enterprise Products Partners L.P.

EPD

Enterprise Products Partners L.P.

HOLD

Current Price

$36.44

Market Cap

80.7B

Sector

Utilities

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRTX
EPD
Founded
1989
1968
Country
United States
United States
Employees
N/A
7300
Industry
EDP Services
Natural Gas Distribution
Sector
Technology
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
115.7B
80.7B
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
VRTX
EPD
Price
$477.08
$36.44
Analyst Decision
Buy
Buy
Analyst Count
29
14
Target Price
$539.69
$38.50
AVG Volume (30 Days)
1.2M
2.7M
Earning Date
05-04-2026
04-28-2026
Dividend Yield
N/A
5.67%
EPS Growth
836.54
N/A
EPS
4.02
N/A
Revenue
$2,488,652,000.00
N/A
Revenue This Year
$10.79
$2.34
Revenue Next Year
$10.47
$6.35
P/E Ratio
$118.22
$13.59
Revenue Growth
46.20
N/A
52 Week Low
$362.50
$30.01
52 Week High
$509.98
$40.17

Technical Indicators

Market Signals
Indicator
VRTX
EPD
Relative Strength Index (RSI) 67.93 40.10
Support Level $420.66 $35.97
Resistance Level $486.26 $38.57
Average True Range (ATR) 11.45 0.62
MACD 3.45 -0.08
Stochastic Oscillator 91.58 18.40

Price Performance

Historical Comparison
VRTX
EPD

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About EPD Enterprise Products Partners L.P.

Enterprise Products Partners is a master limited partnership that transports and processes natural gas, natural gas liquids, crude oil, refined products, and petrochemicals. It is one of the largest midstream companies, with operations servicing most producing regions in the continental US. Enterprise is particularly dominant in the NGL market and is one of the few MLPs that provide midstream services across the full hydrocarbon value chain.

Share on Social Networks: